ロード中...
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA damage repair (DDR) genes. BRCA1/2 mutations occur at 1–7% across biliary tract cancers (BTCs), but a broader spectrum of...
保存先:
| 出版年: | Medicines (Basel) |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7555445/ https://ncbi.nlm.nih.gov/pubmed/32878011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicines7090054 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|